Press Releases

10.04.2017

AmerisourceBergen, Blue Cross Blue Shield Association, Pfizer and Prime Therapeutics Join Walgreens to Combat Prescription Drug Abuse by Expanding Safe Medication Disposal Program

09.27.2017

Pfizer Declares 32-Cent Fourth-Quarter 2017 Dividend

09.27.2017

Bavencio (avelumab) Approved for Merkel Cell Carcinoma in Japan

09.26.2017

Patti LaBelle and Pfizer Work Together to Educate Baby Boomers About the Risk of Pneumococcal Pneumonia

09.21.2017

National Sickle Cell Disease Poll of African Americans Dispels Long-Held Views

09.21.2017

New Global Report Finds Majority of People at High Risk of Stroke Not Being Screened for Common Risk Factors

09.20.2017

European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma

09.20.2017

Pfizer Goes To Court To Allow Competition For Biologics And Expand Options For Patients

09.19.2017

Pfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT® in Patients at High Risk of Recurrent Renal Cell Carcinoma after Surgery

09.14.2017

Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

09.11.2017

Pfizer Presents Overall Survival Data of XALKORI in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer

09.09.2017

Pfizer Presents Positive Pivotal Data for PF-05280014, an Investigational Biosimilar to Herceptin® (trastuzumab), at the European Society for Medical Oncology (ESMO) 2017 Congress